About
Pressroom
Resources
Get Updates
Issues
Access to Medicines
Funding the Fight
Health Justice
Transparency & Accountability
PEPFAR Watch
Blog
Our Impact
Take Action
Do something now
DONATE
Access to Medicines
The European Union, Led by Germany’s Chancellor Merkel, Chokes Off Progress on Intellectual Property Waiver ...
Access to Medicines
Disinformation, Diversion, and Delay: The Real Text of the European Union’s Communication to the WTO TRIPS C...
Access to Medicines
The Impracticality of Relying on Compulsory Licenses to Expand Production Capacity for COVID-19 Vaccines
Access to Medicines
Debunking Pharma’s Talking Points on the TRIPS Waiver
Access to Medicines
Securing the TRIPS Waiver the World Needs: What Comes Next?
Access to Medicines
Pfizer and BioNTech Profiteering Exposed – More than Enough is Enough
Access to Medicines
Biden Can’t Correct Vaccine Apartheid on Big Pharma’s Terms
Access to Medicines
Expanding Vaccine Manufacturing Capacity Solely Within the Pharma Cartel is a Recipe for Perpetual Vaccine Apa...
Access to Medicines
New ViiV license with the Medicines Patent Pool expands access but eviscerates transparency
Access to Medicines
South Africa and India’s Proposal to Waive Recognition and Enforcement of Intellectual Property Rights for C...
Access to Medicines
Moderna Responds to Activist Pressure, But In the Race for Our Lives, We Need More Than Baby Steps
Access to Medicines
In Addition to Outrageous Prices and Preferential Supply to the US only, Gilead’s Allowance for Compulsory L...
Access to Medicines
U.S.-, China- and EU-First Nationalism and COVID-19 Technology Hoarding Push the Rest of the World to the End ...
Access to Medicines
Gilead Remdesivir Licenses: Half Measures are Not Nearly Good Enough
Access to Medicines
Without a Global Approach to Deadly Inequities in Access to Possible COVID-19 Treatments and Vaccines, Legisla...
SEE MORE
